Ascendis Pharma A/S
ASND Nasdaq· Pharmaceutical Preparations
Last close · Oct 30, 2026
$251.27
KIRA · Stoqly’s AI analyst, in plain words
- Ascendis Pharma A/S had $812M of revenue in fiscal 2025, up 106.4% on the year before. Over five years, revenue changed +152.4% a year on average.
- Its operating margin was −18.9%, up 57.7 pts: of every 100 in sales, about −19 is left after running the business.
- Ascendis Pharma A/S lost $257M in fiscal 2025.
- Ascendis Pharma A/S returned $19.6M to shareholders in fiscal 2025. The diluted share count rose 4.7%.
- Ascendis Pharma A/S owes $122M more than it holds in cash.
Market cap
$15.2B
P/E
—
Revenue
$812M
Net income
−$257M
Free cash flow
—
Operating margin
−18.9%
Ascendis Pharma A/S in 30 seconds · fiscal 2025
Are sales growing?
+106.4%
Yes. Sales grew 106.4% last year.
Does it make a profit?
−31.7%
No. It lost money last year.
Is debt under control?
$122M
Risky. It owes more than it holds in cash and has no operating profit to repay it.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Ascendis Pharma A/S does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Feb 11, 2026
- Legal name
- Ascendis Pharma A/S
- CIK
- 0001612042
Ascendis Pharma A/S · ASND · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $9.2M | $53.8M | $288M | $393M | $812M |
| Revenue growth | 16.1% | 484.7% | 436.3% | 36.4% | 106.4% |
| Gross margin | 54.7% | 76.3% | 83.4% | 87.8% | 86.8% |
| Operating margin | −5,808.6% | −1,097.9% | −170.8% | −76.7% | −18.9% |
| Net income | −$454M | −$613M | −$521M | −$409M | −$257M |
| Net margin | −4,931.6% | −1,139.6% | −180.5% | −104.0% | −31.7% |
| Diluted EPS | −$8.28 | −$10.93 | −$9.25 | −$7.06 | −$4.24 |
| Cash | |||||
| Cash from operations | −$494M | −$521M | −$505M | −$331M | $60.8M |
| Capital expenditure | $28.0M | $15.2M | $2.6M | — | — |
| Free cash flow | −$522M | −$536M | −$508M | — | — |
| FCF margin | −5,674.4% | −997.0% | −176.1% | — | — |
| Share buybacks | $25.6M | $111M | $0.0M | $0.0M | $19.6M |
| Share count change | 8.2% | 2.4% | 0.4% | 2.9% | 4.7% |
| Debt and strength | |||||
| Cash and short-term investments | $505M | $474M | $433M | $581M | $724M |
| Debt incl. finance leases | $119M | $426M | $603M | $793M | $846M |
| Shareholders' equity | $1.0B | $281M | −$161M | −$110M | −$191M |
| Current ratio | 8.0x | 5.4x | 1.0x | 1.2x | 1.0x |
| Interest coverage | −115.5x | −18.3x | −10.3x | −4.3x | −1.7x |
| Returns and quality | |||||
| Return on capital | −68.7% | −200.8% | −4,627.4% | −233.2% | — |
| Return on equity | −44.7% | −95.6% | −868.5% | — | — |
| Return on tangible equity | −45.3% | −218.2% | — | — | — |
| Piotroski F-score | 2 | 3 | 3 | 6 | 5 |
Insiders bought, 12 months
$0.8M
2 insiders
Insiders sold, 12 months
$5.5M
3 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Ascendis Pharma A/S · ASND · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $251.27 a share, the company is worth $15.2B.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001612042). Latest version: stoqly.net/companies/asnd. Data updated November 1, 2026. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.